Phosphate binder therapy for attainment of K/DOQI™ bone metabolism guidelines

Kidney International, Supplement

Volumn 68, Issue 96, 2005, Pages

  Nolan, Charles R ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Calcium acetate; Cardiovascular calcification; Hypercalcemia; Metabolic acidosis; Sevelamer hydrochloride

Indexed keywords

ATORVASTATIN; BICARBONATE; BONE MORPHOGENETIC PROTEIN; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; COLESTILAN; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; VITAMIN D; CALCIMIMETIC AGENT; CINACALCET; PHOSPHORUS; VITAMIN D DERIVATIVE;

ACIDEMIA; AGE DISTRIBUTION; ANION EXCHANGE; BICARBONATE BLOOD LEVEL; BLOOD VESSEL CALCIFICATION; BONE METABOLISM; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC DIARRHEA; CHRONIC INFLAMMATION; CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; DIALYSATE; DRUG COST; DYSLIPIDEMIA; ENDOTHELIUM INJURY; GENETIC PREDISPOSITION; HUMAN; HYPERINSULINEMIA; HYPERPHOSPHATEMIA; HYPERTENSION; HYPOCALCEMIA; METABOLIC ACIDOSIS; NONHUMAN; OXIDATIVE STRESS; PARATHYROID CELL; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HORMONE RELEASE; PATHOPHYSIOLOGY; PHOSPHATE BLOOD LEVEL; PRACTICE GUIDELINE; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; SMOKING; URINE PH; BLOOD; BONE; CHRONIC DISEASE; KIDNEY DISEASE; METABOLISM; REVIEW; ARTERY CALCIFICATION; BRAIN DISEASE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HEMODIALYSIS; KIDNEY FAILURE; LONG TERM CARE; MEDICAL ASSESSMENT; MORTALITY; OSTEOMALACIA; RISK FACTOR;

BONE AND BONES; CHRONIC DISEASE; HUMANS; KIDNEY DISEASES; PHOSPHATES; PRACTICE GUIDELINES;

EID: 26044474918     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00449.x     Document Type: Conference Paper

References (27)

1. BLOCK GA, HULBERT-SHEARON TE, LEVIN NW, PORT FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31:607-617, 1998
2. GANESH SK, STACK AG, LEVIN NW, et al: Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12:2131-2138, 2001
3. NATIONAL KIDNEY FOUNDATION: K/DOQI™ clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(Suppl 3):S1-S202, 2003
4. SILVER J: Pathogenesis of parathyroid dysfunction in end-stage renal disease. Adv Renal Replacement Ther 9:159-167, 2002
5. SILVER J, KILAV R, NAVEH-MANY T: Mechanisms of secondary hyperparathyroidism. Am J Physiol Renal Physiol 283:F367-F376, 2002
6. CHERTOW GM, BURKE SK, LAZARUS JM, et al: Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 29:66-71, 1997
7. SLATOPOLSKY EA, BURKE SK, DILLON MA: RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int 55:299-307, 1999
8. QUNIBI WY, HOOTKINS RE, MCDOWELL LL, et al: Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 65:1914-1926, 2004
9. CHERTOW GM, BURKE SK, RAGGI P, TREAT TO GOAL WORKING GROUP: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252, 2002
10. HURST PE, MORRISON RBI, TIMONER J, et al: The effect of anion-exchange resins on faecal anions. Comparison with calcium salts and aluminium hydroxide. Clin Sci 24:189-200, 1963
11. RUBINSTEIN R, HOWARD AV, WRONG OM: In vivo dialysis of faeces as a method of stool analysis. IV. The organic anion component. Clin Sci 37:549-564, 1969
12. BREZINA B, QUNIBI WY, NOLAN CR: Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications. Kidney Int (Suppl 90):S39-S45, 2004
13. BUSHINSKY DA: Net calcium efflux from live bone during chronic metabolic, but not respiratory, acidosis. Am J Physiol 256:F836-F842, 1998
14. BUSHINSKY DA, FRICK KK: The effects of acid on bone. Curr Opin Nephrol Hypertens 9:369-379, 2000
15. BUSHINSKY DA, NILSSON EL: Additive effects of acidosis and parathyroid hormone on mouse osteoblastic and osteoclastic function. Am J Physiol 269:C1364-C1370, 1995
16. BAILEY JL, WANG X, ENGLAND BK, et al: The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway. J Clin Invest 97:1447-1453, 1996
17. BALLMER PE, MCNURLAN MA, HULTER HN, et al: Chronic metabolic acidosis decreases albumin synthesis and induces negative nitrogen balance in humans. J Clin Invest 95:39-45, 1995
18. NATIONAL KIDNEY FOUNDATION: K/DOQI™ clinical practice guidelines for nutrition in chronic renal failure. Am J Kidny Dis 35(Suppl 2):S1-S140, 2000
19. QUNIBI WY, NOLAN CR, AYUS JC: Cardiovascular calcification in patients with end-stage renal disease: A century-old phenomenon. Kidney Int (Suppl 82):73-80, 2002
20. DAVIES MR, LUND RJ, HRUSKA KA: BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Nephrol 14:1559-1567, 2003
21. GOODMAN WG, GOLDIN J, KUIZON BD, et al: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478-1483, 2000
22. GUÉRIN AP, LONDON GM, MARCHAIS SJ, METIVIER E: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15:1014-1021, 2000
23. CHERTOW GM, RAGGI P, CHASAN-TABER S, et al: Determinants of progressive vascular calcification in hemodialysis patients. Nephrol Dial Transplant 19:1489-1496, 2004
24. CALLISTER TQ, RAGGI P, COOIL B, et al: Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med 339:1972-1978, 1998
25. ACHENBACH S, ROPERS D, POHLE K, et al: Influence of lipid-lowering therapy on the progression of coronary artery calcification: A prospective evaluation. Circulation 106:1077-1082, 2002
26. NITTA K, AKIBA T, NIHEI H: Colestimide co-administered with atorvastatin attenuates the progression of vascular calcification in hemodialysis patients. Nephrol Dial Transplant 19:2156, 2004
27. MANNS B, STEVENS L, MISKULIN D, et al: A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int 66:1239-1247, 2004